Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of a specific share transaction rather than a financial results report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details a specific increase in shareholdings by a director following a dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: January 10, 2012.
- Individual Involved: Mr. D E Troy.
- Transaction Type: Increase in interest in Ordinary share ADRs via dividend reinvestment.
- Transaction Price: $46.13 per ADR.
- Volume: 274.072 ADRs.
- Dividend Date: The reinvestment followed a dividend paid to shareholders on January 5, 2012.